Reduction of circulating cholesterol and apolipoprotein levels during sepsis

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 3, 1999, Pages 357-362

  Fraunberger, Peter ^a   Schaefer, Steffen ^b   Werdan, Karl ^b   Walli, Autar K ^a   Seidel, Dietrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cytokines; Hypocholesterolemia; IL 6; Inflammation; Lipoproteins; Mortality; Sepsis; TNF receptors; TNF

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; CYTOKINE; GROWTH FACTOR; LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CYTOKINE PRODUCTION; HOMEOSTASIS; HUMAN; HYPOCHOLESTEROLEMIA; IMMUNE RESPONSE; INFLAMMATION; LIPID METABOLISM; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

ANIMALS; APOLIPOPROTEINS; CHOLESTEROL; CYTOKINES; HUMANS; SEPSIS;

EID: 0032894020     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.059     Document Type: Conference Paper

References (59)

1. Chauffard A, Richet C, Grigaut A. La cholesterinemia au cours de la tuberculose pulmonaire. Compt Rend Soc Biol 1911; lxx: 276-7.
2. Kipp HA. Variation in the cholesterol content of the serum in pneumonia. J Biol Chem 1920; 44:215-37.
3. Coombes EJ, Shakespeare PG, Batstone GF. Lipoprotein changes after burn injury in man. J Trauma 1980; 20:971-5.
4. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986; 32:142-5.
5. Sammalkorpi K, Valtonen V, Kertulla Y, Nikkilä E, Taskinen M-R. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37: 859-65.
6. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentration in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 1996; 24:584-9.
7. Elliot DC, Wiles CE. Low lipid concentration in critical illness: hypocholesterolemia among trauma patients [letter]. Crit Care Med 1997; 25:1437-9.
8. Akgün S, Ertel NH, Mosenthal A, Oser W. Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute phase response. J Lab Clin Med 1998; 131:103-8.
9. Windler E, Ewers-Grabow U, Thiery J, Walli A, Seidel D, Greten H. The prognostic value of hypocholesterolemia in hospitalized patients. Clin Invest 1994; 72:939-43.
10. Pacelli F, Doglietto GB, Alfieri S, Piccioni E, Sgadari A, Gui D, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996; 131: 641-5.
11. Hardaróttir I, Grünfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opinion Lipidology 1994; 5:207-15.
12. Fraunberger P, Pilz G, Cremer P, Werdan K, Walli AK. Association of serum TNF levels with decrease of cholesterol during septic shock. Shock 1998; 10:1-5.
13. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacological study. J Natl Cancer Inst 1988; 80:1039-44.
14. Van Gameren MM, Willemse PHB, Mulder NH, Limburg PC, Groen HJM, Vellenga E, et al. Effects of recombinant interleukin-6 in cancer patients: a phase I-II study. Blood 1994; 5:1434-41.
15. Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE. Hypocholesterolemia in patients treated with recombinant interleukin-2: appearence of remnant-like lipoproteins. J Clin Oncol 1989; 7:1573-7.
16. Nimer SD, Champlin RE, Golde DW. Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. J Am Med Assoc 1988; 260:3297-300.
17. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, et al. Cytokines decrease apolipoprotein accumulation in medium from HepG2 cells. Arterioscler Throm 1994; 14:8-13.
18. Yokoyama K, Ishibashi T, Yi-qiang L, Nagayoshi A, Teramoto T, Maruyama Y. Interleukin-1β and interleukin-6 increase levels of apolipoprotein B mRNA and decrease accumulation of its protein in culture medium of HepG2 cells. J Lip Res 1998; 39:103-13.
19. Song H, Saito K, Fujigaki S, Noma A, Ishiguro H, Nagatsu T, et al. IL-1 beta and TNF-alpha suppress apolipoprotein (apo) E secretion and apo A-I expression in HepG2 cells. Cytokine 1998; 10:275-80.
20. Chait A, RUSS R, Albers JJ, Bierman EL. Platelet-derived growth factor stimulates activity of low density lipoprotein receptors. Proc Natl Acad Sci 1980; 77: 4084-8.
21. Harada K, Shimano H, Kawakami M, Ishibashi S, Gotoda T, Mori N, et al. Effect of tumor necrosis factor/cachectin on the activity of the low density lipoprotein receptor on human skin fibroblast. Biochem Biophys Res Comm 1990 172:1022-7.
22. Ishibashi S, Inaba T, Shimano H, Harada K, Inoue I, Mokuno H, et al. Monocyte colony-stimulating factor enhances uptake and degradation of acetylated low density lipoproteins and cholesterol esterification in human monocyte-derived macrophages. J Biol Chem 1990; 265:14109-17.
23. Aviram M. Platelet secretory products enhance LDL receptor activity and inhibit scavenger receptor activity in human monocyte derived macrophages. Metabolism 1989; 38:425-30.
24. Grove RI, Mazzucco C, Allegretto N, Kiener PA, Spitalny G, Radka SF, et al. Macrophage-derived factors increase low density lipoprotein uptake and receptor number in cultured human liver cells. J Lipid Res 1991; 32:1889-97.
25. Stopeck AT, Nicholson AC, Mancini FP, Hajjar DP. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993; 268:17489-94.
26. Moorby CD, Gherardi E, Dovey DE, Godliman C, Bowyer DE. Transforming growth factor and Interleukin-1β stimulates LDL receptor activity in HepG2 cells. Atherosclerosis 1992; 97: 21-8.
27. Graham A, Russell LJ. Stimulation of low-density lipoprotein uptake in HepG2 cells by epidermal growth factor via a tyrosine kinase-dependent, but protein kinase C-independent, mechanism. Biochem J 1994; 298:579-84.
28. Pak YK, Kanuck MP, Berrios D, Briggs MR, Cooper AD, Ellsworth JL. Activation of LDL receptor gene expression in HepG2 cells by hepatocyte growth factor. J Lipid Res 1996; 37:985-98.
29. Moran CS, Campbell JH, Campbell GR. Human leukemia inhibitory factor upregulates LDL receptors on liver cells and decreases serum cholesterol in the cholesterol-fed rabbit. ArteriosclerThromb Vasc Biol 1997; 17:1267-73.
30. Engelmann H, Novick D, Wallach D. Tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265:1531-6.
31. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci 1992; 89:4845-9.
32. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993; 132:2246-53.
33. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987; 80:184-90.
34. Ettinger WH, Miller LD, Albers JJ, Smith TK, Parks JS. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res 1990; 31:1099-107.
35. Ettinger WH, Miller LA, Smith TK, Parks JS. Effect of interleukin-1 alpha on lipoprotein lipids in cynomolgus monkeys: comparison to tumor necrosis factors. Biochim Biophys Acta 1992; 1128:186-192.
36. Chajek-Shaul T, Friedman G, Stein O, Shiloni E, Etienne J, Stein Y. Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. Biochim Biophys Acta 1989; 1001:316-24.
37. Gouni I, Oka K, Etienne J, Chan L. Endotoxin-induced hypertriglyceridemia is mediated by suppression of lipoprotein lipase at a post-transcriptional level. J Lipid Res 1993; 34:139-46.
38. Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992; 33:1765-76.
39. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987; 262:8390-4.
40. Lanza-Jacoby S, Phetteplace H, Sedkova N, Knee G. Sequential alterations in tissue lipoprotein lipase, triglyceride secretion rates, and serum tumor necrosis factor alpha during Escherichia coli bacteremic sepsis in relation to the development of hypertriglyceridemia. Shock 1998; 9:46-51.
41. Feingold KR, Doerrler W, DinarelloCA, Fiers W, Grunfeld C. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 1992; 130:10-6.
42. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52:4113-6.
43. Doerrler W, Feingold KR, Grunfeld C. Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. Cytokine 1994; 6:478-84.
44. Grunfeld C, Adi S, Soued M, Moser A, Fiers W, Feingold KR. Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. Cancer Res 1990; 50:4233-8.
45. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86:696-702.
46. Read TE, Grunfeld C, Kumwenda ZL, Calhoun MC, Kane JP, Feingold KR, et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med 1995; 182:267-72.
47. Harris HW, Grunfeld C, Feingold KR, Read TE, Kane JP, Jones AL, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91:1028-34.
48. Read TE, Harris HW, Grunfeld C, Feingold KR, Calhoun MC, Kane JP, et al. Chylomicrons enhance endotoxin excretion in bile. Infect Immun 1993; 61:3496-502.
49. Pensen PC, Oosten M, Bill E, Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest 1997; 99:2438-45.
50. Hubsch AP, Powell FS, Lerch PG. Doran-JE. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23.
51. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995; 63:2041-6.
52. Weinstock C, Ullrich H, Hohe R, Berg A, Baumstark MW, Frey I, et al. Low density lipoproteins inhibit endotoxin activation of monocytes. Arterioscler Thromb 1992; 12:341-7.
53. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61:5140-6.
54. Netea MG, De-Bont N, Demacker PN, Kullberg BJ, Jacobs LE, Verver-Jansen TJ, et al. Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells. Infect Immun 1998; 66:2365-7.
55. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181:1743-54.
56. Pajkart D, Doran JE, Koster F, Lerch PG, Arnet B, van-der-Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-8.
57. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94:4318-23.
58. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393:790-3.
59. Rotondo D, Davidson J. Lipid metabolism [editorial]. Curr Opin Lipidol 1998; 9:503-5.